New hope for lung cancer patients with brain tumors: drug combo enters final testing

This study tests whether a new drug called furmonertinib, given with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous NSCLC) that has spread to the brain. About 380 adults whose cancer has brain metastases will be randomly assigned to one of three treatment groups. The goal is to see which approach keeps the cancer from growing longer and is safe.